Alternating chemotherapy in advanced gastric cancer. A phase II study.
A phase II study with an alternating chemotherapeutic scheme, in advanced gastric cancer was conducted. Twenty-two patients were treated with cisplatin and mitomycin C on day 1 and BCNU and doxorubicin on day 28. Tegafur p.o. was given daily from the start to the end of chemotherapy. This scheme was repeated every four weeks. Response rate was 25% (2 complete and 3 partial). However, remissions were short lived, and median survival for the entire group was 7 months. Haematological and gastrointestinal toxicities were severe. In conclusion, the low response rate and the high toxicity of this regimen preclude its use for the treatment of gastric cancer.
Feliu
J
J
S. Oncología Médica, H. La Paz, U.A.M. Madrid, Spain.
Girón
C G
CG
González-Baron
M
M
Berrocal
A
A
Barón-Saura
J M
JM
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002330:Carmustine / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000009:adverse effects; D009362:Neoplasm Metastasis; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors
D000970:Antineoplastic Agents; D008937:Mitomycins; D005641:Tegafur; D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin; D002330:Carmustine